Intestinal transporters for endogenic and pharmaceutical organic anions: The challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug-drug interactions

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 11, 2012, Pages 1523-1548

  Grandvuinet, Anne Sophie ^a   Vestergaard, Henrik Tang ^b   Rapin, Nicolas ^c   Steffansen, Bente ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b DANISH MEDICINES AGENCY   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

in vitro models; intestinal membrane transporters; kinetic parameters; organic anions; prediction of clinically relevant drug drug interactions

Indexed keywords

ANION; APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER; ATAZANAVIR; BECLOMETASONE; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CYCLOSPORIN A; DAUNORUBICIN; DEXAMETHASONE; DIGOXIN; INTESTINAL TRANSPORTER FOR ORGANIC ANION; LOPINAVIR; MEMBRANE PROTEIN; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 3; MONOCARBOXYLATE TRANSPORTER 4; MONOCARBOXYLATE TRANSPORTER 5; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 6; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1A2; ORGANIC ANION TRANSPORTING POLYPEPTIDE 2B1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 3A1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 4A1; ORGANIC SOLUTE TRANSPORTER ALPHA BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALYTICAL PARAMETERS; CUT OFF VALUE; DRUG DRUG INTERACTION; DRUG INTERACTION; DRUG SOLUBILITY; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; KINETICS; NONHUMAN; PREDICTION; PROTEIN EXPRESSION; REVIEW; STANDARDIZATION;

ANIMALS; ANIONS; BIOLOGICAL TRANSPORT; DRUG INTERACTIONS; HUMANS; INTESTINES; MODELS, BIOLOGICAL; ORGANIC ANION TRANSPORTERS; PHARMACEUTICAL PREPARATIONS;

EID: 84867580115     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01505.x     Document Type: Review

References (222)

1. Glaeser H,. Importance of P-glycoprotein for drug-drug interactions. Handb Exp Pharmacol 2011; 201: 285-297.
2. Aszalos A,. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov Today 2007; 12: 838-843.
3. Zhou SF,. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008; 38: 802-832.
4. Food and Drug Administration. Drug interaction studies-study design, data analysis, and implications for dosing and labeling. Guidance for Industry (Draft). 2006.
5. Food and Drug Administration. Drug interaction studies-study design, data analysis, and implications for dosing and labeling recommendations. Guidance for Industry (Draft). 2012.
6. European Medicines Agency. Guideline on the investigation of drug interactions (Draft). 2010.
7. Giacomini KM, et al,. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236.
8. Kunta JR, Sinko PJ,. Intestinal drug transporters: in vivo function and clinical importance. Curr Drug Metab 2004; 5: 109-124.
9. Murakami T, Takano M,. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 2008; 4: 923-939.
10. Niemi M,. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8: 787-802.
11. Shore PA, et al,. The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Ther 1957; 119: 361-369.
12. Meier Y, et al,. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos 2007; 35: 590-594.
13. Hruz P, et al,. Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. Gut 2006; 55: 395-402.
14. Hilgendorf C, et al,. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 2007; 35: 1333-1340.
15. Craddock AL, et al,. Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol 1998; 274: G157-G169.
16. Englund G, et al,. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 2006; 29: 269-277.
17. Gutmann H, et al,. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol 2005; 70: 695-699.
18. Seithel A, et al,. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur J Pharm Sci 2006; 28: 291-299.
19. Glaeser H, et al,. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007; 81: 362-370.
20. Taipalensuu J, et al,. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 2001; 299: 164-170.
21. Maubon N, et al,. Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR. Fundam Clin Pharmacol 2007; 21: 659-663.
22. Urquhart BL, et al,. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics 2008; 18: 439-448.
23. Maliepaard M, et al,. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61: 3458-3464.
24. Gill RK, et al,. Expression and membrane localization of MCT isoforms along the length of the human intestine. Am J Physiol Cell Physiol 2005; 289: C846-C852.
25. Ritzhaupt A, et al,. Identification and characterization of a monocarboxylate transporter (MCT1) in pig and human colon: its potential to transport L-lactate as well as butyrate. J Physiol 1998; 513 (Pt 3): 719-732.
26. Lin RY, et al,. Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter. J Biol Chem 1998; 273: 28959-28965.
27. Berggren S, et al,. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 2007; 4: 252-257.
28. Prime-Chapman HM, et al,. Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J Pharmacol Exp Ther 2004; 311: 476-484.
29. Scheffer GL, et al,. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest 2002; 82: 193-201.
30. Tachibana T, et al,. Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res 2010; 27: 442-446.
31. Flens MJ, et al,. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996; 148: 1237-1247.
32. Zimmermann C, et al,. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos 2005; 33: 219-224.
33. Cao X, et al,. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 2006; 23: 1675-1686.
34. Beck K, et al,. Analysis of ABCC6 (MRP6) in normal human tissues. Histochem Cell Biol 2005; 123: 517-528.
35. Tamai I, et al,. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000; 273: 251-260.
36. Sai Y, et al,. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos 2006; 34: 1423-1431.
37. Kobayashi D, et al,. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 2003; 306: 703-708.
38. Fujiwara K, et al,. Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology 2001; 142: 2005-2012.
39. Ballatori N, et al,. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 2005; 42: 1270-1279.
40. Kullak-Ublick GA, et al,. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120: 525-533.
41. Nozawa T, et al,. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 2004; 308: 438-445.
42. Ming X, et al,. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. Mol Pharm 2011; 8: 1677-1686.
43. Varma MV, et al,. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm 2011; 8: 1303-1313.
44. Food and Drug Administration. Guidance for industry-bioavailability and bioequivalence studies for orally administered drug products-general considerations. 2003.
45. Nies AT, et al,. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol 2008; 4: 545-568.
46. Benet LZ, et al,. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003; 4: 393-398.
47. Roberts MS, et al,. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 2002; 41: 751-790.
48. Dawson PA,. Role of the intestinal bile acid transporters in bile acid and drug disposition. Handb Exp Pharmacol 2011; 201: 169-203.
49. Xia X, et al,. Bile acid interactions with cholangiocytes. World J Gastroenterol 2006; 12: 3553-3563.
50. Alpini G, et al,. Functional expression of the apical Na+-dependent bile acid transporter in large but not small rat cholangiocytes. Gastroenterology 1997; 113: 1734-1740.
51. Lee W, et al,. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 2005; 280: 9610-9617.
52. Zhou SF, et al,. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008; 15: 1981-2039.
53. Klaassen CD, Aleksunes LM,. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 2010; 62: 1-96.
54. Balakrishnan A, et al,. Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm Res 2005; 22: 1269-1280.
55. Zheng X, et al,. Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm 2009; 6: 1591-1603.
56. Suzuki M, et al,. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 2003; 278: 22644-22649.
57. Pavek P, et al,. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 2005; 312: 144-152.
58. Merino G, et al,. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos 2005; 33: 614-618.
59. Bierman WF, et al,. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother 2010; 65: 1672-1680.
60. Chen ZS, et al,. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003; 63: 4048-4054.
61. Hirano M, et al,. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 2005; 68: 800-807.
62. Li J, et al,. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos 2011; 39: 1196-1202.
63. Imai Y, et al,. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 2003; 64: 610-618.
64. Karlsson JE, et al,. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug Metab Dispos 2010; 38: 705-714.
65. Chearwae W, et al,. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol Cancer Ther 2006; 5: 1995-2006.
66. Shukla S, et al,. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 2006; 45: 8940-8951.
67. Litman T, et al,. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000; 113 (Pt 11): 2011-2021.
68. van Herwaarden AE, et al,. Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol 2007; 27: 1247-1253.
69. Woodward OM, et al,. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A 2009; 106: 10338-10342.
70. Shukla S, et al,. The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther 2007; 6: 3279-3286.
71. Merino G, et al,. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 2006; 34: 690-695.
72. Lagas JS, et al,. Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos 2009; 37: 129-136.
73. Zhang Y, et al,. BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 2005; 22: 2023-2034.
74. Wang X, et al,. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol 2003; 63: 65-72.
75. Pulido MM, et al,. Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther 2006; 29: 279-287.
76. Mitomo H, et al,. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J 2003; 373: 767-774.
77. Gedeon C, et al,. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta 2006; 27: 1096-1102.
78. Kis E, et al,. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis 2009; 68: 1201-1207.
79. Ando T, et al,. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos 2007; 35: 1873-1879.
80. Maliepaard M, et al,. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001; 7: 935-941.
81. Kim HS, et al,. The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol 2007; 64: 645-654.
82. Volk EL, et al,. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 2000; 60: 3514-3521.
83. Volk EL, Schneider E,. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003; 63: 5538-5543.
84. Maliepaard M, et al,. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59: 4559-4563.
85. Fujino H, et al,. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol 2005; 57: 1305-1311.
86. Huang L, et al,. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 2006; 34: 738-742.
87. Kitamura S, et al,. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 2008; 36: 2014-2023.
88. Manning Fox JE, et al,. Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol 2000; 529 (Pt 2): 285-293.
89. Okamura A, et al,. Transport and uptake of nateglinide in Caco-2 cells and its inhibitory effect on human monocarboxylate transporter MCT1. Br J Pharmacol 2002; 137: 391-399.
90. Kobayashi M, et al,. Inhibitory effects of statins on human monocarboxylate transporter 4. Int J Pharm 2006; 317: 19-25.
91. Wang Q, Morris ME,. The role of monocarboxylate transporter 2 and 4 in the transport of gamma-hydroxybutyric acid in mammalian cells. Drug Metab Dispos 2007; 35: 1393-1399.
92. Leier I, et al,. ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int 2000; 57: 1636-1642.
93. Jedlitschky G, et al,. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem J 1997; 327 (Pt 1): 305-310.
94. Versantvoort CH, et al,. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem Pharmacol 1994; 48: 1129-1136.
95. Renes J, et al,. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol 1999; 126: 681-688.
96. Tamai I, et al,. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther 2000; 295: 146-152.
97. Evers R, et al,. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 2000; 83: 375-383.
98. Bakos E, et al,. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 2000; 57: 760-768.
99. Loe DW, et al,. ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem 1996; 271: 9683-9689.
100. Chen ZS, et al,. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 1999; 55: 921-928.
101. Zelcer N, et al,. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J 2003; 371: 361-367.
102. Qian YM, et al,. Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. J Biol Chem 2001; 276: 6404-6411.
103. Zeng H, et al,. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res 2001; 61: 7225-7232.
104. Paumi CM, et al,. Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry 2003; 42: 5429-5437.
105. Jedlitschky G, et al,. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 1996; 56: 988-994.
106. Stride BD, et al,. Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol 1997; 52: 344-353.
107. Cui Y, et al,. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999; 55: 929-937.
108. Morrow CS, et al,. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol 2006; 69: 1499-1505.
109. Reid G, et al,. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A 2003; 100: 9244-9249.
110. Williams GC, et al,. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother 2002; 46: 3456-3462.
111. Flanagan SD, et al,. Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology 2002; 64: 126-134.
112. Paulusma CC, et al,. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem J 1999; 338 (Pt 2): 393-401.
113. Loe DW, et al,. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 1996; 271: 9675-9682.
114. Srinivas RV, et al,. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998; 42: 3157-3162.
115. Priebe W, et al,. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem Biophys Res Commun 1998; 247: 859-863.
116. Guo A, et al,. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos 2002; 30: 457-463.
117. Kamisako T, et al,. Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology 1999; 30: 485-490.
118. Matsushima S, et al,. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 2008; 36: 663-669.
119. Chen ZS, et al,. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 1999; 56: 1219-1228.
120. Tang F, et al,. Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res 2002; 19: 773-779.
121. Huisman MT, et al,. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002; 16: 2295-2301.
122. Hooijberg JH, et al,. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999; 59: 2532-2535.
123. Spears KJ, et al,. Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem Pharmacol 2005; 69: 415-423.
124. Nakagomi-Hagihara R, et al,. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos 2006; 34: 862-869.
125. Sasaki M, et al,. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem 2002; 277: 6497-6503.
126. Zeng H, et al,. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res 2000; 60: 4779-4784.
127. Akita H, et al,. Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res 2002; 19: 34-41.
128. Zelcer N, et al,. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 2001; 276: 46400-46407.
129. Zhang DW, et al,. Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. Biochemistry 2003; 42: 9989-10000.
130. Zelcer N, et al,. Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem J 2003; 369: 23-30.
131. Hagenbuch B,. Cellular entry of thyroid hormones by organic anion transporting polypeptides. Best Pract Res Clin Endocrinol Metab 2007; 21: 209-221.
132. Chen ZS, et al,. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001; 276: 33747-33754.
133. Lai L, Tan TM,. Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J 2002; 361: 497-503.
134. van Aubel RA, et al,. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002; 13: 595-603.
135. Chen ZS, et al,. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 2002; 62: 3144-3150.
136. Adachi M, et al,. Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem 2002; 277: 38998-39004.
137. Tian Q, et al,. Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab 2006; 7: 105-118.
138. Jedlitschky G, et al,. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000; 275: 30069-30074.
139. Wijnholds J, et al,. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 2000; 97: 7476-7481.
140. Wielinga P, et al,. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 2005; 65: 4425-4430.
141. Belinsky MG, et al,. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 2002; 62: 6172-6177.
142. Ilias A, et al,. Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem 2002; 277: 16860-16867.
143. Briz O, et al,. Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 2003; 371: 897-905.
144. Kullak-Ublick GA, et al,. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 1995; 109: 1274-1282.
145. Kullak-Ublick GA, et al,. Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology 1997; 113: 1295-1305.
146. Kullak-Ublick GA, et al,. Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett 1998; 424: 173-176.
147. Maeda T, et al,. Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm 2007; 4: 85-94.
148. Cvetkovic M, et al,. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27: 866-871.
149. Bossuyt X, et al,. Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J Hepatol 1996; 25: 733-738.
150. Ianculescu AG, et al,. Transport of thyroid hormones is selectively inhibited by 3-iodothyronamine. Mol Biosyst 2010; 6: 1403-1410.
151. Hu S, et al,. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008; 14: 3141-3148.
152. Badagnani I, et al,. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 2006; 318: 521-529.
153. van Montfoort JE, et al,. Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther 1999; 291: 147-152.
154. Ho RH, et al,. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006; 130: 1793-1806.
155. Su Y, et al,. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm 2004; 1: 49-56.
156. Kato K, et al,. Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport. Mol Pharm 2010; 7: 1747-1756.
157. Pizzagalli F, et al,. Identification of steroid sulfate transport processes in the human mammary gland. J Clin Endocrinol Metab 2003; 88: 3902-3912.
158. Grube M, et al,. Modification of OATP2B1-mediated transport by steroid hormones. Mol Pharmacol 2006; 70: 1735-1741.
159. Vaidyanathan S, et al,. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 2008; 48: 1323-1338.
160. Tamai I, et al,. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 2001; 18: 1262-1269.
161. Hirano M, et al,. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006; 34: 1229-1236.
162. Noe J, et al,. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 2007; 35: 1308-1314.
163. Satoh H, et al,. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005; 33: 518-523.
164. Grube M, et al,. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 2006; 80: 607-620.
165. Kis O, et al,. pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther 2010; 334: 1009-1022.
166. Treiber A, et al,. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 2007; 35: 1400-1407.
167. Kopplow K, et al,. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol 2005; 68: 1031-1038.
168. Annaert P, et al,. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 2010; 40: 163-176.
169. Bachmakov I, et al,. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes 2008; 57: 1463-1469.
170. Adachi H, et al,. Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol 2003; 285: F1188-F1197.
171. Huber RD, et al,. Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am J Physiol Cell Physiol 2007; 292: C795-C806.
172. Seward DJ, et al,. Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem 2003; 278: 27473-27482.
173. Doyle LA, et al,. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998; 95: 15665-15670.
174. Cole SP, et al,. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-1654.
175. Xia CQ, et al,. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions. Expert Opin Drug Metab Toxicol 2005; 1: 595-611.
176. Schwabedissen HE, Kroemer HK,. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ ABCG2). Handb Exp Pharmacol 2011; 201: 325-371.
177. Kalliokoski A, Niemi M,. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705.
178. Fagerholm U,. Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation. J Pharm Pharmacol 2008; 60: 535-542.
179. Lennernas H,. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007; 37: 1015-1051.
180. Rao A, et al,. The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc Natl Acad Sci U S A 2008; 105: 3891-3896.
181. Shitara Y, et al,. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 2005; 45: 689-723.
182. Gao J, et al,. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res 2001; 18: 171-176.
183. Hagenbuch B, Gui C,. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 2008; 38: 778-801.
184. Rautio J, et al,. In vitro p-glycoprotein inhibition assays for
185. Keogh JP, Kunta JR,. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 2006; 27: 543-554.
186. Kim RB, et al,. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16: 408-414.
187. Balimane PV, et al,. P-gp inhibition potential in cell-based models: which 'calculation' method is the most accurate? AAPS J 2008; 10: 577-586.
188. Troutman MD, Thakker DR,. Efflux ratio cannot assess P-glycoprotein- mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 2003; 20: 1200-1209.
189. Korjamo T, et al,. Decrease in intracellular concentration causes the shift in Km value of efflux pump substrates. Drug Metab Dispos 2007; 35: 1574-1579.
190. Sugano K, et al,. Estimation of Michaelis-Menten constant of efflux transporter considering asymmetric permeability. Int J Pharm 2011; 418: 161-167.
191. Cook JA, et al,. Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm 2010; 7: 398-411.
192. Sugimoto H, et al,. Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage. J Pharm Sci 2011; 100: 4013-4023.
193. Tachibana T, et al,. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. Curr Drug Metab 2010; 11: 762-777.
194. Shirasaka Y, et al,. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci 2008; 97: 553-565.
195. Tang F, et al,. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 2002; 19: 765-772.
196. Sun H, Pang KS,. Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study. Drug Metab Dispos 2008; 36: 102-123.
197. Bentz J, et al,. The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km. Pharm Res 2005; 22: 1667-1677.
198. Tran TT, et al,. The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. Biophys J 2005; 88: 715-738.
199. Rolsted K, et al,. Simulating kinetic parameters in transporter mediated permeability across Caco-2 cells. A case study of estrone-3-sulfate. Eur J Pharm Sci 2011; 44: 218-226.
200. Hayeshi R, et al,. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 2008; 35: 383-396.
201. Sun H, et al,. The Caco-2 cell monolayer: usefulness and limitations. Expert Opin Drug Metab Toxicol 2008; 4: 395-411.
202. Artursson P, Karlsson J,. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885.
203. Rubas W, et al,. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J Pharm Sci 1996; 85: 165-169.
204. Lennernäs H, et al,. Comparison between active and passive drug transport in human intestinal epithelial (caco-2) cells in vitro and human jejunum in vivo. Int J Pharm 1996; 127: 103-107.
205. Sugano K, et al,. Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov 2010; 9: 597-614.
206. Matsson P, et al,. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 2009; 26: 1816-1831.
207. Gram LK, et al,. Impact of carriers in oral absorption: permeation across Caco-2 cells for the organic anions estrone-3-sulfate and glipizide. Eur J Pharm Sci 2009; 37: 378-386.
208. Grandvuinet AS, Steffansen B,. Interactions between organic anions on multiple transporters in Caco-2 cells. J Pharm Sci 2011; 100: 3817-3830.
209. Tian X, et al,. Knocking down transport: applications of RNA interference in the study of drug transport proteins. Drug Metab Rev 2005; 37: 705-723.
210. Lee SH, Sinko PJ,. siRNA-getting the message out. Eur J Pharm Sci 2006; 27: 401-410.
211. Hu M, et al,. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin Drug Metab Toxicol 2011; 7: 49-62.
212. Zhang L, et al,. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 2008; 38: 709-724.
213. Fenner KS, et al,. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009; 85: 173-181.
214. In vitro P-GP IC50 Working Group. Results of the vesicle subteam. 2011. SOLVO Biotechnology Science Letter.
215. Schiller C, et al,. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2005; 22: 971-979.
216. Food and Drug Administration. Guidance for industry-waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2000.
217. European Medicines Agency. Guideline on the investigation for bioequivalence. 2010.
218. Kleberg K, et al,. Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies. J Pharm Pharmacol 2010; 62: 1656-1668.
219. Yazdanian M, et al,. The 'high solubility' definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm Res 2004; 21: 293-299.
220. Lennernas H, Abrahamsson B,. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol 2005; 57: 273-285.
221. Wu CY, Benet LZ,. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22: 11-23.
222. Shugarts S, Benet LZ,. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 2009; 26: 2039-2054.